Canaccord analyst William Plovanic raised the firm’s price target on AngioDynamics to $18 from $17 and keeps a Buy rating on the shares. The firm updated estimates on AngioDynamics to reflect the press release that the company has sold its PICC and Midline Product portfolios to Spectrum Vascular for $45M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANGO:
- AngioDynamics price target lowered to $14 from $18 at H.C. Wainwright
- AngioDynamics sells PICC, Midline product portfolios for up to $45M in cash
- AngioDynamics Announces Key Leadership and Board Changes
- FDA clears AngioDynamics Auryon XL Catheter to treat Peripheral Arterial Disease
- AngioDynamics’ Long-Time Director Meteny Retires